LIVIVO - Search results -

Search results

Result 1 - 10 of total 74

Search options

Book ; Conference proceedings: From discovery to clinical practice

Conley, Barbara A.

NCI-EORTC present 2nd International Meeting on Cancer Diagnostic ; an interactive workshop focused on practical methods for bringing promising prognostic and predictive markers from the research laboratory to the bedside ; June 26 - 29, 2002, Grand Hyatt Hotel, Washington, DC, USA ; abstracts

(The international journal of biological markers ; 17, Suppl. 2)

2002

Institution	National Cancer Institute
Event/congress	International Meeting on Cancer Diagnostics (2, 2002, WashingtonDC)
Author's details	conference co-chairpersons Barbara A. Conley
Series title	The international journal of biological markers ; 17, Suppl. 2
Collection
Language	English
Size	S63 S. : graph. Darst.
Publisher	Wichtig
Publishing place	Milano
Publishing country	Italy
Document type	Book ; Conference proceedings
HBZ-ID	HT013431190
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 2491 -17,2,Suppl.-	not available for loan	Zeitschriften-Lesesaal

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Genomically guided cancer treatments: from "promising" to "clinically useful".

Conley, Barbara A

Journal of the National Cancer Institute

2015 Volume 107, Issue 7

MeSH term(s)	Animals ; Antineoplastic Agents/pharmacology ; Biomarkers, Tumor/genetics ; Decision Support Techniques ; Drugs, Investigational/pharmacology ; Genomics ; Humans ; Mutation ; Neoplasms/drug therapy ; Neoplasms/genetics ; Precision Medicine/trends
Chemical Substances	Antineoplastic Agents ; Biomarkers, Tumor ; Drugs, Investigational
Language	English
Publishing date	2015-07
Publishing country	United States
Document type	Comment ; Editorial
ZDB-ID	2992-0
ISSN	1460-2105 ; 0027-8874 ; 0198-0157
ISSN (online)	1460-2105
ISSN	0027-8874 ; 0198-0157
DOI	10.1093/jnci/djv168
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.131: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical Application of Liquid Biopsies.

Williams, P Mickey / Conley, Barbara A

JAMA oncology

2016 Volume 2, Issue 8, Page(s) 1003–1005

MeSH term(s)	Adenocarcinoma/diagnosis ; Adenocarcinoma/genetics ; Clinical Decision-Making ; DNA, Neoplasm/analysis ; DNA, Neoplasm/blood ; High-Throughput Nucleotide Sequencing ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/genetics ; Mutation ; Polymerase Chain Reaction/methods ; Precision Medicine ; Proto-Oncogene Proteins p21(ras)/genetics ; Receptor, Epidermal Growth Factor/genetics ; Sequence Analysis, DNA
Chemical Substances	DNA, Neoplasm ; KRAS protein, human ; EGFR protein, human (EC 2.7.10.1) ; Receptor, Epidermal Growth Factor (EC 2.7.10.1) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
Language	English
Publishing date	2016-08-01
Publishing country	United States
Document type	Editorial
ISSN	2374-2445
ISSN (online)	2374-2445
DOI	10.1001/jamaoncol.2016.0240
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Molecular analysis for therapy choice: NCI MATCH.

Conley, Barbara A / Doroshow, James H

Seminars in oncology

2014 Volume 41, Issue 3, Page(s) 297–299

MeSH term(s)	Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/analysis ; Decision Making ; Humans ; Molecular Targeted Therapy ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/metabolism
Chemical Substances	Antineoplastic Agents ; Biomarkers, Tumor
Language	English
Publishing date	2014-06
Publishing country	United States
Document type	Editorial
ZDB-ID	189220-4
ISSN	1532-8708 ; 0093-7754
ISSN (online)	1532-8708
ISSN	0093-7754
DOI	10.1053/j.seminoncol.2014.05.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1348: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Treatment of advanced head and neck cancer: what lessons have we learned?

Conley, Barbara A

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2006 Volume 24, Issue 7, Page(s) 1023–1025

MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Squamous Cell/chemistry ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/radiotherapy ; Chemotherapy, Adjuvant ; Clinical Trials as Topic ; Gene Expression Regulation, Neoplastic ; Head and Neck Neoplasms/chemistry ; Head and Neck Neoplasms/drug therapy ; Head and Neck Neoplasms/pathology ; Head and Neck Neoplasms/radiotherapy ; Humans ; Predictive Value of Tests ; Prognosis ; Radiotherapy, Adjuvant ; Receptor, Epidermal Growth Factor/analysis ; Research Design ; Risk Factors ; Selection Bias ; Survival Analysis ; Up-Regulation
Chemical Substances	Receptor, Epidermal Growth Factor (EC 2.7.10.1)
Language	English
Publishing date	2006-03-01
Publishing country	United States
Document type	Comment ; Editorial
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.2005.05.0682
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.

Clinical cancer research : an official journal of the American Association for Cancer Research

2024 Volume 30, Issue 7, Page(s) 1273–1280

Abstract: Purpose: NCI-MATCH assigned patients with advanced cancer and progression on prior treatment, based on genomic alterations in pretreatment tumor tissue. Arm J (EAY131-J) evaluated the combination of trastuzumab/pertuzumab (HP) across HER2-amplified ... ...

Abstract	Purpose: NCI-MATCH assigned patients with advanced cancer and progression on prior treatment, based on genomic alterations in pretreatment tumor tissue. Arm J (EAY131-J) evaluated the combination of trastuzumab/pertuzumab (HP) across HER2-amplified tumors. Patients and methods: Eligible patients had high levels of HER2 amplification [copy number (CN) ≥7] detected by central next-generation sequencing (NGS) or through NCI-designated laboratories. Patients with breast/gastroesophageal adenocarcinoma and those who received prior HER2-directed therapy were excluded. Enrollment of patients with colorectal cancer was capped at 4 based on emerging data. Patients received HP IV Q3 weeks until progression or unacceptable toxicity. Primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS) and overall survival (OS). Results: Thirty-five patients were enrolled, with 25 included in the primary efficacy analysis (CN ≥7 confirmed by a central lab, median CN = 28). Median age was 66 (range, 31-80), and half of all patients had ≥3 prior therapies (range, 1-11). The confirmed ORR was 12% [3/25 partial responses (colorectal, cholangiocarcinoma, urothelial cancers), 90% confidence interval (CI) 3.4%-28.2%]. There was one additional partial response (urothelial cancer) in a patient with an unconfirmed ERBB2 copy number. Median PFS was 3.3 months (90% CI 2.0-4.1), and median OS 9.4 months (90% CI 5.0-18.9). Treatment-emergent adverse events were consistent with prior studies. There was no association between HER2 CN and response. Conclusions: HP was active in a selection of HER2-amplified tumors (non-breast/gastroesophageal) but did not meet the predefined efficacy benchmark. Additional strategies targeting HER2 and potential resistance pathways are warranted, especially in rare tumors.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/pathology ; Progression-Free Survival ; Receptor, ErbB-2/metabolism ; Trastuzumab/adverse effects ; Trastuzumab/therapeutic use
Chemical Substances	Antibodies, Monoclonal, Humanized ; pertuzumab (K16AIQ8CTM) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK)
Language	English
Publishing date	2024-03-04
Publishing country	United States
Document type	Randomized Controlled Trial ; Journal Article
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-23-0633
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.

JCO precision oncology

2024 Volume 8, Page(s) e2300454

Abstract: Purpose: The National Cancer Institute Molecular Analysis for Therapy Choice trial is a signal-finding genomically driven platform trial that assigns patients with any advanced refractory solid tumor, lymphoma, or myeloma to targeted therapies on the ... ...

Abstract	Purpose: The National Cancer Institute Molecular Analysis for Therapy Choice trial is a signal-finding genomically driven platform trial that assigns patients with any advanced refractory solid tumor, lymphoma, or myeloma to targeted therapies on the basis of next-generation sequencing results. Subprotocol E evaluated osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with Methods: Eligible patients had Results: A total of 19 patients were enrolled: 17 were evaluable for toxicity and 13 for efficacy. The median age of the 13 included in the efficacy analysis was 63 years, 62% had Eastern Cooperative Oncology Group performance status 1, and 31% received >three previous systemic therapies. The most common tumor type was brain cancers (54%). The ORR was 15.4% (n = 2 of 13; 90% CI, 2.8 to 41.0) and 6-month PFS was 16.7% (90% CI, 0 to 34.4). The two confirmed RECIST responses were observed in a patient with neuroendocrine carcinoma not otherwise specified ( Conclusion: In this pretreated cohort, osimertinib did not meet the prespecified end point threshold for efficacy, but responses were seen in a neuroendocrine carcinoma with an
MeSH term(s)	United States ; Humans ; Middle Aged ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Carcinoma, Non-Small-Cell Lung/genetics ; ErbB Receptors/genetics ; National Cancer Institute (U.S.) ; Antineoplastic Agents/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Mutation ; Carcinoma, Neuroendocrine/drug therapy ; Acrylamides ; Aniline Compounds ; Indoles ; Pyrimidines
Chemical Substances	osimertinib (3C06JJ0Z2O) ; ErbB Receptors (EC 2.7.10.1) ; Antineoplastic Agents ; Protein Kinase Inhibitors ; Acrylamides ; Aniline Compounds ; Indoles ; Pyrimidines
Language	English
Publishing date	2024-04-09
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article
ISSN	2473-4284
ISSN (online)	2473-4284
DOI	10.1200/PO.23.00454
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine.

Tsimberidou, Apostolia M / Said, Rabih / Staudt, Louis M / Conley, Barbara A / Takebe, Naoko

Cancer journal (Sudbury, Mass.)

2019 Volume 25, Issue 4, Page(s) 296–299

Abstract: Widely available molecular profiling technology, including next-generation sequencing has changed the landscape of drug development in cancer. An increasing number of clinical trials in early drug development require patient selection based on molecular ... ...

Abstract	Widely available molecular profiling technology, including next-generation sequencing has changed the landscape of drug development in cancer. An increasing number of clinical trials in early drug development require patient selection based on molecular alterations. Concurrently, efforts to identify molecular alterations in tumors that exhibited exceptional response after systemic treatment with standard or investigational agents have been published or are in progress. These discoveries may ultimately serve as predictive markers or "actionable mutations" for future therapies. To test the feasibility of collecting the archival tissues from proposed exceptional responder patients and successful subsequent molecular profiling, the National Cancer Institute opened a nationwide exceptional responder initiative protocol in 2014. In addition, an increasing number of exceptional responder cases have been identified and published from academia institutions. The Network of Enigmatic Exceptional Responders study uses crowdsourcing to identify exceptional responders and will molecularly profile tumors to discern molecular correlates with exceptional response. In this review, we discuss the potential role of exceptional responder molecular analysis in new biomarker discovery efforts to further advance precision medicine in oncology therapeutics.
MeSH term(s)	Disease Management ; Disease Susceptibility ; Humans ; Medical Oncology/methods ; Medical Oncology/standards ; National Cancer Institute (U.S.) ; Neoplasms/diagnosis ; Neoplasms/drug therapy ; Neoplasms/etiology ; Precision Medicine/methods ; Precision Medicine/standards ; United States
Language	English
Publishing date	2019-07-24
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2018400-1
ISSN	1540-336X ; 1528-9117 ; 1081-4442
ISSN (online)	1540-336X
ISSN	1528-9117 ; 1081-4442
DOI	10.1097/PPO.0000000000000392
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4470: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 163: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Phase II Study of Erdafitinib in Patients With Tumors With

JCO precision oncology

2024 Volume 8, Page(s) e2300406

Abstract: Purpose: Despite fibroblast growth factor receptor (: Methods: EAY131-K1 was an open-label, single-arm, phase II study with central confirmation of presence of : Results: Thirty-five patients were enrolled into this study with 18 included in the ... ...

Abstract	Purpose: Despite fibroblast growth factor receptor ( Methods: EAY131-K1 was an open-label, single-arm, phase II study with central confirmation of presence of Results: Thirty-five patients were enrolled into this study with 18 included in the prespecified primary efficacy analysis. The median age of the 18 patients was 60 years, and 78% had received ≥3 previous lines of therapy. There were no confirmed responses to erdafitinib; however, five patients experienced stable disease (SD) as best response. One patient with an Conclusion: Erdafitinib did not meet its primary end point of efficacy as determined by ORR in treatment-refractory solid tumors harboring
MeSH term(s)	Humans ; Middle Aged ; Neoplasms/drug therapy ; Neoplasms/genetics ; Pyrazoles/therapeutic use ; Quinoxalines ; United States ; Urinary Bladder Neoplasms ; Receptors, Fibroblast Growth Factor/genetics
Chemical Substances	erdafitinib (890E37NHMV) ; Pyrazoles ; Quinoxalines ; Receptors, Fibroblast Growth Factor
Language	English
Publishing date	2024-04-11
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article
ISSN	2473-4284
ISSN (online)	2473-4284
DOI	10.1200/PO.23.00406
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

JCO precision oncology

2024 Volume 8, Page(s) e2300407

Abstract: Purpose: Subprotocol K2 (EAY131-K2) of the NCI-MATCH platform trial was an open-label, single-arm, phase II study designed to evaluate the antitumor efficacy of the oral FGFR1-4 inhibitor, erdafitinib, in patients with tumors harboring FGFR1-4 mutations ...

Abstract	Purpose: Subprotocol K2 (EAY131-K2) of the NCI-MATCH platform trial was an open-label, single-arm, phase II study designed to evaluate the antitumor efficacy of the oral FGFR1-4 inhibitor, erdafitinib, in patients with tumors harboring FGFR1-4 mutations or fusions. Methods: Central confirmation of tumor FGFR1-4 mutations or fusions was required for outcome analysis. Patients with urothelial carcinoma were excluded. Enrolled subjects received oral erdafitinib at a starting dose of 8 mg daily continuously until intolerable toxicity or disease progression. The primary end point was objective response rate (ORR) with key secondary end points of safety, progression-free survival (PFS), and overall survival (OS). Results: Thirty-five patients were enrolled, and 25 patients were included in the primary efficacy analysis as prespecified in the protocol. The median age was 61 years, and 52% of subjects had received ≥3 previous lines of therapy. The confirmed ORR was 16% (4 of 25 [90% CI, 5.7 to 33.0], Conclusion: This study met its primary end point in patients with several pretreated solid tumor types harboring FGFR1-3 mutations or fusions. These findings support advancement of erdafitinib for patients with fibroblast growth factor receptor-altered tumors outside of currently approved indications in a potentially tumor-agnostic manner.
MeSH term(s)	Humans ; Middle Aged ; Mutation ; Pyrazoles/therapeutic use ; Pyrazoles/adverse effects ; Quinoxalines ; Urinary Bladder Neoplasms ; Neoplasms/drug therapy ; Neoplasms/genetics ; Receptors, Fibroblast Growth Factor/genetics
Chemical Substances	erdafitinib (890E37NHMV) ; Pyrazoles ; Quinoxalines ; Receptors, Fibroblast Growth Factor
Language	English
Publishing date	2024-04-11
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article
ISSN	2473-4284
ISSN (online)	2473-4284
DOI	10.1200/PO.23.00407
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED